
Tetsuichi Yoshizato

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9232280/publications.pdf Version: 2024-02-01



Τετειμομι Υσεμιζατο

#	Article	IF	CITATIONS
1	Integrated molecular analysis of clear-cell renal cell carcinoma. Nature Genetics, 2013, 45, 860-867.	21.4	955
2	Mutational landscape and clonal architecture in grade II and III gliomas. Nature Genetics, 2015, 47, 458-468.	21.4	729
3	Integrated molecular analysis of adult T cell leukemia/lymphoma. Nature Genetics, 2015, 47, 1304-1315.	21.4	659
4	Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers. Nature, 2016, 534, 402-406.	27.8	536
5	Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. New England Journal of Medicine, 2015, 373, 35-47.	27.0	508
6	Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature, 2019, 565, 312-317.	27.8	476
7	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	30.7	372
8	Dynamics of clonal evolution in myelodysplastic syndromes. Nature Genetics, 2017, 49, 204-212.	21.4	348
9	Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood, 2017, 129, 2347-2358.	1.4	268
10	Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro-Oncology, 2018, 20, 66-77.	1.2	225
11	Recurrent somatic mutations underlie corticotropin-independent Cushing's syndrome. Science, 2014, 344, 917-920.	12.6	177
12	Frequent mutations that converge on the NFKBIZ pathway in ulcerative colitis. Nature, 2020, 577, 260-265.	27.8	168
13	Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia, 2019, 33, 2867-2883.	7.2	148
14	Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia. Nature Communications, 2018, 9, 3649.	12.8	140
15	Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood, 2018, 131, 215-225.	1.4	124
16	Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria. Journal of Clinical Investigation, 2014, 124, 4529-4538.	8.2	103
17	Variegated RHOA mutations in adult T-cell leukemia/lymphoma. Blood, 2016, 127, 596-604.	1.4	98
18	Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia, 2019, 33, 1687-1699.	7.2	98

Τετѕиісні Yoshizato

#	Article	IF	CITATIONS
19	A temporal shift of the evolutionary principle shaping intratumor heterogeneity in colorectal cancer. Nature Communications, 2018, 9, 2884.	12.8	82
20	Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis. Nature Medicine, 2021, 27, 1239-1249.	30.7	78
21	Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. Cancer Cell, 2021, 39, 793-809.e8.	16.8	65
22	Gene expression and risk of leukemic transformation in myelodysplasia. Blood, 2017, 130, 2642-2653.	1.4	64
23	Physiological Srsf2 P95H expression causes impaired hematopoietic stem cell functions and aberrant RNA splicing in mice. Blood, 2018, 131, 621-635.	1.4	64
24	Telomere attrition and candidate gene mutations preceding monosomy 7 in aplastic anemia. Blood, 2015, 125, 706-709.	1.4	60
25	Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes. Nature Communications, 2019, 10, 5386.	12.8	53
26	Combined Cohesin–RUNX1 Deficiency Synergistically Perturbs Chromatin Looping and Causes Myelodysplastic Syndromes. Cancer Discovery, 2020, 10, 836-853.	9.4	51
27	Origins of myelodysplastic syndromes after aplastic anemia. Blood, 2017, 130, 1953-1957.	1.4	50
28	Somatic PHF6 mutations in 1760 cases with various myeloid neoplasms. Leukemia, 2016, 30, 2270-2273.	7.2	35
29	Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia. Blood Advances, 2020, 4, 5165-5173.	5.2	33
30	Molecular pathogenesis of disease progression in MLL-rearranged AML. Leukemia, 2019, 33, 612-624.	7.2	26
31	Clinical Significance of Serum-Soluble Interleukin-2 Receptor in Patients With Follicular Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 410-416.	0.4	22
32	Effects of universal vs bedside leukoreductions on the alloimmunization to platelets and the platelet transfusion refractoriness. Transfusion and Apheresis Science, 2015, 52, 112-121.	1.0	20
33	Sustained clonal hematopoiesis by HLA-lacking hematopoietic stem cells without driver mutations in aplastic anemia. Blood Advances, 2018, 2, 1000-1012.	5.2	20
34	A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial. EBioMedicine, 2021, 66, 103327.	6.1	16
35	Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia. International Journal of Hematology, 2011, 93, 400-402.	1.6	15
36	Clonally related diffuse large B-cell lymphoma and interdigitating dendritic cell sarcoma sharing MYC translocation. Haematologica, 2018, 103, e553-e556.	3.5	14

Тетѕиісні Yoshizato

#	Article	IF	CITATIONS
37	Biological Analysis of SRSF2 Mutations in Leukemogenesis. Blood, 2012, 120, 1282-1282.	1.4	13
38	Aged healthy mice acquire clonal hematopoiesis mutations. Blood, 2022, 139, 629-634.	1.4	13
39	The landscape of genetic aberrations in myxofibrosarcoma. International Journal of Cancer, 2022, 151, 565-577.	5.1	13
40	A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia. Leukemia, 2018, 32, 839-843.	7.2	12
41	Prediction model for CD34 positive cell yield in peripheral blood stem cell collection on the fourth day after G-CSF administration in healthy donors. International Journal of Hematology, 2013, 98, 56-65.	1.6	9
42	Impact of Somatic Mutations on Outcome in Patients with MDS after Stem-Cell Transplantation. Blood, 2015, 126, 711-711.	1.4	9
43	Clinical Impacts of Germline <i>DDX41</i> Mutations on Myeloid Neoplasms. Blood, 2020, 136, 38-40.	1.4	7
44	Frequent Activating Somatic Alterations in T-Cell Receptor / NF-κb Signaling in Adult T-Cell Leukemia/Lymphoma. Blood, 2015, 126, 113-113.	1.4	7
45	Genetic Predispositions to Myeloid Neoplasms Caused By Germline DDX41 Mutations. Blood, 2015, 126, 2843-2843.	1.4	7
46	Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia. Journal of Internal Medicine, 2022, 292, 262-277.	6.0	7
47	Comprehensive Analysis of Aberrant RNA Splicing in Myelodysplastic Syndromes. Blood, 2014, 124, 826-826.	1.4	6
48	Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data. Blood, 2018, 132, 1801-1801.	1.4	4
49	Chronological Analysis of Clonal Evolution in Acquired Aplastic Anemia. Blood, 2014, 124, 253-253.	1.4	4
50	Disseminated tuberculosis following unrelated cord blood transplantation for refractory peripheral T-cell lymphoma: Clinical role of serum procalcitonin levels. Journal of Infection, 2011, 62, 237-240.	3.3	3
51	Molecular Heterogeneity in Peripheral T-Cell Lymphoma Not Otherwise Specified Revealed By Comprehensive Mutational Profiling. Blood, 2016, 128, 2927-2927.	1.4	3
52	Genotype-Phenotype Relationships and Therapeutic Targets in Acute Erythroid Leukemia. Blood, 2020, 136, 17-18.	1.4	3
53	Distinct, Ethnic, Clinical, and Genetic Characteristics of Myelodysplastic Syndromes with Der(1;7). Blood, 2019, 134, 5392-5392.	1.4	2
54	Different Mutant Splicing Factors Cause Distinct Missplicing Events and Give Rise to Different Clinical Phenotypes in Myelodysplastic Syndromes. Blood, 2015, 126, 139-139.	1.4	2

Τετςμιςμι Υοςμιζατο

#	Article	IF	CITATIONS
55	Srsf2 P95H Mutation Causes Impaired Stem Cell Repopulation and Hematopoietic Differentiation in Mice. Blood, 2015, 126, 1649-1649.	1.4	2
56	Serial Sequencing in Myelodysplastic Syndromes Reveals Dynamic Changes in Clonal Architecture and Allows for a New Prognostic Assessment of Mutations Detected in Cross-Sectional Testing. Blood, 2015, 126, 709-709.	1.4	2
57	NGS-Based Copy Number Analysis in 1,185 Patients with Myeloid Neoplasms. Blood, 2016, 128, 955-955.	1.4	2
58	Whole-Genome Sequencing of Primary Central Nervous System Lymphoma and Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 4112-4112.	1.4	2
59	PPM1D and DNMT3A Mutations in Myelodysplasia and Clonal Hematopoiesis. Blood, 2019, 134, 1709-1709.	1.4	2
60	Mutations in Triple-Negative Patients with Myeloproliferative Neoplasms. Blood, 2019, 134, 5395-5395.	1.4	2
61	Pulmonary mucormycosis with embolism: two autopsied cases of acute myeloid leukemia. International Journal of Clinical and Experimental Pathology, 2014, 7, 3449-53.	0.5	2
62	Der(1;7)(q10;p10) Presents with a Unique Genetic Profile and Frequent <i>ETNK1</i> Mutations in Myeloid Neoplasms. Blood, 2021, 138, 1513-1513.	1.4	2
63	Integrative Analysis of Primary <i>SF3B1 mt</i> Ring Sideroblasts Provides Fundamental Insights into MDS-RS Pathogenesis and Dyserythropoiesis. Blood, 2021, 138, 146-146.	1.4	2
64	Simple but powerful prognostic scoring model for MALT lymphoma: a retrospective study. Annals of Hematology, 2013, 92, 421-423.	1.8	1
65	Novel Molecular Pathogenesis and Therapeutic Target in Acute Erythroid Leukemia. Blood, 2019, 134, 914-914.	1.4	1
66	Whole Exome Sequencing Reveals Clonal Evolution Pattern and Driver Mutations Of Relapsed Pediatric AML. Blood, 2013, 122, 1410-1410.	1.4	1
67	Landscape of Genetic Alterations in Adult T-Cell Leukemia/Lymphoma. Blood, 2014, 124, 75-75.	1.4	1
68	Two Novel Distinct Subtypes of Myeloid Neoplasms Molecularly Associated with Histone H3K36 Methylations. Blood, 2015, 126, 2841-2841.	1.4	1
69	Role Of Sf3b1 On Hematopoiesis. Blood, 2013, 122, 600-600.	1.4	1
70	Genetic Basis of Primary Central Nervous System Lymphoma. Blood, 2015, 126, 2687-2687.	1.4	1
71	Genetic Profile of Acute Erythroid Leukemia. Blood, 2016, 128, 40-40.	1.4	1
72	Molecular Characterization Of Adult T-Cell Leukemia/Lymphoma. Blood, 2013, 122, 1766-1766.	1.4	0

Τετςμιςμι Υοςμιζατο

#	Article	IF	CITATIONS
73	Spectrum Of Genetic Alterations In Acquired Aplastic Anemia. Blood, 2013, 122, 2464-2464.	1.4	0
74	Novel Biological Effects and Distinct Patterns of Rhoa Mutations in Adult T-Cell Leukemia/Lymphoma and Angioimmunoblastic T Cell Lymphoma. Blood, 2014, 124, 2215-2215.	1.4	0
75	Next-Generation Sequencing Reveal Proviral Genome and Transcriptome in Adult T-Cell Leukemia/Lymphoma. Blood, 2015, 126, 3882-3882.	1.4	0
76	Landscape of DNA Methylation and Genetic Profiles in 291 Patients with Myelodysplastic Syndromes. Blood, 2015, 126, 5205-5205.	1.4	0
77	Myelodysplastic Syndrome (MDS)-Determining Clonal Events at Presentation of Aplastic Anemia (AA). Blood, 2015, 126, 1652-1652.	1.4	0
78	Clinical Significance of Mutations and Copy Number Lesions on Prognosis of Patients with MDS after Unrelated Bone Marrow Transplantation. Blood, 2016, 128, 1971-1971.	1.4	0
79	Integrated Molecular Analysis of Myelodysplastic Syndromes Using Whole Genome Sequencing. Blood, 2016, 128, 5512-5512.	1.4	0
80	Combined DNA and Transcriptome Sequencing Reveals Discrete Subtypes of Myelodysplasia. Blood, 2016, 128, 1974-1974.	1.4	0
81	the Impact of Clonal Dynamics on Prognosis and Outcome in Myelodysplastic Syndromes. Blood, 2016, 128, 4287-4287.	1.4	0
82	Landscape of Subclonal Mutations in Myelodysplastic Syndromes (MDS) Allows for a Novel Hierarchy of Clonal Advantage By Combining Germline and Somatic Mutations. Blood, 2016, 128, 957-957.	1.4	0
83	Invariant Patterns of Clonal Succession Determines Specific Phenotypic and Clinical Features of Myelodysplastic Syndromes (MDS). Blood, 2018, 132, 104-104.	1.4	0
84	Analysis of Genomic Predispositions to Sporadic Myeloid Neoplasms Mediated By DDX41 in Japan. Blood, 2018, 132, 4371-4371.	1.4	0
85	Distinct Features of Chip-Derived and De Novo MDS. Blood, 2018, 132, 2572-2572.	1.4	0
86	Genome-Wide Analysis of Non-Coding Alterations in Pan-Myeloid Cancers Using Whole Genome Sequencing. Blood, 2018, 132, 103-103.	1.4	0
87	DNA Methylation and Genetic Profiles in 320 Patients with Myelodysplastic Syndromes. Blood, 2018, 132, 1799-1799.	1.4	0
88	Novel and Significant Impact of Germline Variants Predisposed to Pathogenic Somatic Mutations and Loss of Heterozygosity (LOH) in Myelodysplastic Syndromes (MDS) and Clonal Hematopoiesis of Indeterminate Potential (CHIP). Blood, 2018, 132, 108-108.	1.4	0
89	Integrated Analysis of Copy-Number Alterations and Gene Mutations in 2,000 Patients with Myeloid Neoplasms. Blood, 2019, 134, 4216-4216.	1.4	0